Inhibikase Therapeutics, INC. (IKT) — 10-K Filings
All 10-K filings from Inhibikase Therapeutics, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Inhibikase Kicks Off Phase 3 for PAH Drug IKT-001, Eyes $8.3B Market
— Mar 26, 2026 Risk: high
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on cardiopulmonary diseases, particularly Pulmonary Arterial Hypertension -
Inhibikase Therapeutics Files 2024 10-K
— Mar 27, 2025 Risk: medium
Inhibikase Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological p -
Inhibikase Therapeutics Files 2023 Annual Report on Form 10-K
— Mar 27, 2024 Risk: medium
Inhibikase Therapeutics, Inc. (IKT) filed a Annual Report (10-K) with the SEC on March 27, 2024. Inhibikase Therapeutics, Inc. filed its annual report on Form 1
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX